News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Histogenics Corporation Selects Pacific Biosciences (PACB) DNA Sequencing Platform To Enhance Human Leukocyte Antigen (HLA) Typing


4/29/2014 9:30:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MENLO PARK, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc., (Nasdaq:PACB) and HistoGenetics, a global leader in Human Leukocyte Antigen (HLA) sequence-based typing (SBT), announced today that HistoGenetics has selected the PacBio DNA Sequencing platform for its unique ability to sequence full-length HLA genes and to provide fully phased HLA alleles. HistoGenetics has purchased two PacBio RS II DNA Sequencing systems, which will be used for HLA typing and will be evaluated as potential replacements for Sanger sequencing.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES